Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?

Brain metastases Extracranial metastases Prognostic score Radiotherapy Survival prediction

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
06 2021
Historique:
received: 18 12 2020
revised: 20 02 2021
accepted: 23 02 2021
pubmed: 7 3 2021
medline: 29 6 2021
entrez: 6 3 2021
Statut: ppublish

Résumé

Survival prediction models may serve as decision-support tools for clinicians who have to assign the right treatment to each patient, in a manner whereby harmful over- or undertreatment is avoided as much as possible. Current models differ regarding their components, the overall number of components and the weighting of individual components. Some of the components are easy to assess, such as age or primary tumor type. Others carry the risk of inter-assessor inconsistency and time-dependent variation. The present publication focuses on issues related to assessment of extracranial metastases and potential surrogates, e.g. blood biomarkers. It identifies areas of controversy and provides recommendations for future research projects, which may contribute to prognostic models with improved accuracy.

Identifiants

pubmed: 33675870
pii: S0167-8140(21)06112-0
doi: 10.1016/j.radonc.2021.02.038
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-20

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Carsten Nieder (C)

Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Electronic address: carsten.nieder@nlsh.no.

Minesh P Mehta (MP)

Department of Radiation Oncology, Miami Cancer Institute, USA.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Laurie E Gaspar (LE)

Department of Radiation Oncology, University of Colorado and Banner MDAnderson of Northern Colorado, USA.

Chad G Rusthoven (CG)

Department of Radiation Oncology, Anschutz Medical Campus, Aurora, USA.

Arjun Sahgal (A)

Department of Radiation Oncology, Sunnybrook Health Sciences Centre and University of Toronto, Canada.

Anca L Grosu (AL)

Department of Radiation Oncology, Medical Center, Medical Faculty, University Freiburg, Germany.

Dirk De Ruysscher (D)

Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Center, GROW, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH